Skip to Content

Idarucizumab Side Effects

For the Consumer

Applies to idarucizumab: intravenous solution

Along with its needed effects, idarucizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking idarucizumab:

Incidence not known
  • Anxiety
  • blurred vision
  • bone pain
  • chills
  • cold sweats
  • coma
  • confusion
  • convulsions
  • cool, pale skin
  • cough
  • dark-colored urine
  • deep or fast breathing with dizziness
  • depression
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • drowsiness
  • fast heartbeat
  • fever
  • general feeling of tiredness or weakness
  • headache
  • hives, itching, or skin rash
  • increased hunger
  • light-colored stools
  • loss of appetite
  • muscle tremors
  • nausea
  • nervousness
  • nightmares
  • numbness of the feet, hands, and around the mouth
  • pain in the chest, groin, or legs, especially the calves
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rapid, deep breathing
  • restlessness
  • seizures
  • severe, sudden headache
  • shakiness
  • slurred speech
  • stomach cramps
  • stomach pain, continuing
  • sudden loss of coordination
  • sudden, severe weakness or numbness in the arm or leg
  • sudden, unexplained shortness of breath
  • tightness in the chest
  • unusual tiredness or weakness
  • vision changes
  • vomiting
  • yellow eyes or skin

For Healthcare Professionals

Applies to idarucizumab: intravenous solution

General

The most common adverse reactions were hypokalemia, delirium, constipation, pyrexia, pneumonia, and headache.[Ref]

Cardiovascular

Common (1% to 10%): Thrombotic events[Ref]

Metabolic

Common (1% to 10%): Hypokalemia[Ref]

Psychiatric

Common (1% to 10%): Delirium[Ref]

Gastrointestinal

Common (1% to 10%): Constipation[Ref]

Other

Common (1% to 10%): Pyrexia[Ref]

Respiratory

Common (1% to 10%): Pneumonia
Frequency not reported: Bronchospasm, hyperventilation[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]

Dermatologic

Frequency not reported: Rash, pruritus[Ref]

Immunologic

Frequency not reported: Hypersensitivity reactions[Ref]

References

1. "Product Information. Praxbind (idaruCIZUMAB)." Boehringer Ingelheim, Ridgefield, CT.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Some side effects of idarucizumab may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide